Restricted Research - Award List, Note/Discussion Page
Fiscal Year: 2023
2468 The University of Texas at San Antonio (144356)
Principal Investigator: Lin, Chin Hsing
Total Amount of Contract, Award, or Gift (Annual before 2011): $ 50,000
Exceeds $250,000 (Is it flagged?): No
Start and End Dates: 9/12/22 - 12/31/23
Restricted Research: YES
Academic Discipline: SCIENCES
Department, Center, School, or Institute: Cos Integrative Biology
Title of Contract, Award, or Gift: Repurposing CRISPR Platform for (Epi)genome Editing in Glioblastoma
Name of Granting or Contracting Agency/Entity:
University of California San Francisco (UCSF)
CFDA: 0
Program Title: none
Note:
SAMs 1.1.1; This research project will study the process of tumorigenesis versus the development of drug resistance involves alterations in various networks and pathways, such complexity limits the efficacy of single-target treatment. To correct these overwhelming aberrances, CRISPR (Clustered Regularly Interspaced Short Palindrome Repeats) technology offers a promising tool to modulate epigenome and gene expression. A programable and reversible CRISPR interference/dCas9 ribonucleoprotein (RNP) platform for (epi)genome editing will be used to manipulating multiple target genes associated with drug resistance. In Year 1, preliminary study will be performed in cell-based assay by comparing primary GBM cells and recurrent GBM cells. The UCSF Brain Tumor Center will provide patient-derived GBM tumor cells, which will be de-identified (no patient identifiers). In parallel with functional assays (proliferation; cell death), a high-throughput microfluidics-based multi-omics with integrated flow sorting and single-cell analysis will be applied to assess the levels of gene and protein expression in response to CRISPRi/dCas9 RNP editing. In Year 2, candidate sgRNA sets will be further tested in 3-D GBM tumor organoid model established in Dr. Linâs laboratory.
Discussion: No discussion notes